{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:47:19Z","timestamp":1777430839231,"version":"3.51.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,8]]},"DOI":"10.7759\/cureus.73286","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T15:49:42Z","timestamp":1731080982000},"source":"Crossref","is-referenced-by-count":5,"title":["Recurrence of Retinopathy of Prematurity Following Anti-vascular Endothelial Growth Factor (Anti-VEGF) Therapy: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Mohammed","family":"Dablouk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed T","family":"Masoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control","volume":"84","author":"Gilbert C","year":"2008","unstructured":"Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008, 84:77-82. 10.1016\/j.earlhumdev.2007.11.009","journal-title":"Early Hum Dev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2020.12.002","article-title":"Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: a meta-analysis of 3,701 eyes","volume":"66","author":"Popovic MM","year":"2021","unstructured":"Popovic MM, Nichani P, Muni RH, Mireskandari K, Tehrani NN, Kertes PJ. Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: a meta-analysis of 3,701 eyes. Surv Ophthalmol. 2021, 66:572-84. 10.1016\/j.survophthal.2020.12.002","journal-title":"Surv Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.semperi.2019.05.002","article-title":"Epidemiology of ROP update - Africa is the new frontier","volume":"43","author":"Gilbert C","year":"2019","unstructured":"Gilbert C, Malik AN, Nahar N, Das SK, Visser L, Sitati S, Ademola-Popoola DS. Epidemiology of ROP update - Africa is the new frontier. Semin Perinatol. 2019, 43:317-22. 10.1053\/j.semperi.2019.05.002","journal-title":"Semin Perinatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.11.001","article-title":"Retinal vasculature development in health and disease","volume":"63","author":"Selvam S","year":"2018","unstructured":"Selvam S, Kumar T, Fruttiger M. Retinal vasculature development in health and disease. Prog Retin Eye Res. 2018, 63:1-19. 10.1016\/j.preteyeres.2017.11.001","journal-title":"Prog Retin Eye Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1084-2756(03)00119-2","article-title":"Pathogenesis of retinopathy of prematurity","volume":"8","author":"Smith LE","year":"2003","unstructured":"Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003, 8:469-73. 10.1016\/S1084-2756(03)00119-2","journal-title":"Semin Neonatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2165\/00128072-200103040-00003","article-title":"The management of retinopathy of prematurity","volume":"3","author":"Reynolds JD","year":"2001","unstructured":"Reynolds JD. The management of retinopathy of prematurity. Paediatr Drugs. 2001, 3:263-72. 10.2165\/00128072-200103040-00003","journal-title":"Paediatr Drugs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000312821","article-title":"Infection, oxygen, and immaturity: interacting risk factors for retinopathy of prematurity","volume":"99","author":"Chen M","year":"2011","unstructured":"Chen M, Citil A, McCabe F, Leicht KM, Fiascone J, Dammann CE, Dammann O. Infection, oxygen, and immaturity: interacting risk factors for retinopathy of prematurity. Neonatology. 2011, 99:125-32. 10.1159\/000312821","journal-title":"Neonatology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.101113998","article-title":"Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity","volume":"98","author":"Hellstrom A","year":"2001","unstructured":"Hellstrom A, Perruzzi C, Ju M, et al.. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A. 2001, 98:5804-8. 10.1073\/pnas.101113998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cne.902330409","article-title":"Development of the subretinal space in the preterm human eye: ultrastructural and immunocytochemical studies","volume":"233","author":"Johnson AT","year":"1985","unstructured":"Johnson AT, Kretzer FL, Hittner HM, Glazebrook PA, Bridges CD, Lam DM. Development of the subretinal space in the preterm human eye: ultrastructural and immunocytochemical studies. J Comp Neurol. 1985, 233:497-505. 10.1002\/cne.902330409","journal-title":"J Comp Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jp.7211475","article-title":"Oxygen and retinopathy of prematurity","volume":"26","author":"Saugstad OD","year":"2006","unstructured":"Saugstad OD. Oxygen and retinopathy of prematurity. J Perinatol. 2006, 26:S46-50; discussion S63-4. 10.1038\/sj.jp.7211475","journal-title":"J Perinatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jp.7211040","article-title":"Arterial oxygen fluctuation and retinopathy of prematurity in very-low-birth-weight infants","volume":"24","author":"York JR","year":"2004","unstructured":"York JR, Landers S, Kirby RS, Arbogast PG, Penn JS. Arterial oxygen fluctuation and retinopathy of prematurity in very-low-birth-weight infants. J Perinatol. 2004, 24:82-7. 10.1038\/sj.jp.7211040","journal-title":"J Perinatol"},{"key":"ref12","article-title":"Disorders of the retina and vitreous","author":"Olitsky SE","year":"2011","unstructured":"Olitsky SE, Hug D, Plummer LS, Stass-Isern M. Disorders of the retina and vitreous. Nelson Textbook of Pediatrics. Kliegman RM, St. Geme J, et al. (ed): Elsevier, Philadelphia (PA); 2011. 2174-81.e1."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.7.991","article-title":"The International Classification of Retinopathy of Prematurity revisited","volume":"123","year":"2005","unstructured":"The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005, 123.991-9. 10.1001\/archopht.123.7.991","journal-title":"Arch Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International Classification of Retinopathy of Prematurity, third edition","volume":"128","author":"Chiang MF","year":"2021","unstructured":"Chiang MF, Quinn GE, Fielder AR, et al.. International Classification of Retinopathy of Prematurity, third edition. Ophthalmology. 2021, 128:e51-68. 10.1016\/j.ophtha.2021.05.031","journal-title":"Ophthalmology"},{"key":"ref15","article-title":"An international classification of retinopathy of prematurity. II. The classification of retinal detachment. The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity","volume":"105","year":"1987","unstructured":"An international classification of retinopathy of prematurity. II. The classification of retinal detachment. The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity. Arch Ophthalmol. 1987, 105.906-12.","journal-title":"Arch Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(98)00284-0","article-title":"Treatment outcome in fellow eyes after laser photocoagulation for retinopathy of prematurity","volume":"127","author":"Brooks SE","year":"1999","unstructured":"Brooks SE, Johnson M, Wallace DK, Paysse EA, Coats DK, Marcus DM. Treatment outcome in fellow eyes after laser photocoagulation for retinopathy of prematurity. Am J Ophthalmol. 1999, 127:56-61. 10.1016\/s0002-9394(98)00284-0","journal-title":"Am J Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(01)00540-1","article-title":"The multicenter study of Early Treatment for Retinopathy of Prematurity (ETROP)","volume":"108","author":"Good WV","year":"2001","unstructured":"Good WV, Hardy RJ. The multicenter study of Early Treatment for Retinopathy of Prematurity (ETROP). Ophthalmology. 2001, 108:1013-4. 10.1016\/s0161-6420(01)00540-1","journal-title":"Ophthalmology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(01)00956-4","article-title":"Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: seven-year outcome","volume":"132","author":"Shalev B","year":"2001","unstructured":"Shalev B, Farr AK, Repka MX. Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: seven-year outcome. Am J Ophthalmol. 2001, 132:76-80. 10.1016\/s0002-9394(01)00956-4","journal-title":"Am J Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3928\/01913913-20100308-05","article-title":"Confluent laser photocoagulation for the treatment of retinopathy of prematurity","volume":"47","author":"Gonzalez VH","year":"2010","unstructured":"Gonzalez VH, Giuliari GP, Banda RM, Guel DA, Wingard M. Confluent laser photocoagulation for the treatment of retinopathy of prematurity. J Pediatr Ophthalmol Strabismus. 2010, 47:81-5; quiz 86-7. 10.3928\/01913913-20100308-05","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery RL","year":"2006","unstructured":"Avery RL, Pearlman J, Pieramici DJ, et al.. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006, 113:1695.e1-15. 10.1016\/j.ophtha.2006.05.064","journal-title":"Ophthalmology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.02.006","article-title":"Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study","volume":"148","author":"Bashshur ZF","year":"2009","unstructured":"Bashshur ZF, Haddad ZA, Schakal AR, Jaafar RF, Saad A, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol. 2009, 148:59-65.e1. 10.1016\/j.ajo.2009.02.006","journal-title":"Am J Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner HA","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011, 364:603-15. 10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl A","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, et al.. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019, 394:1551-9. 10.1016\/S0140-6736(19)31344-3","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20211124-01","article-title":"Aflibercept for retinopathy of prematurity: a systematic review and meta-analysis","volume":"52","author":"Chen PJ","year":"2021","unstructured":"Chen PJ, Rossin EJ, Vavvas DG. Aflibercept for retinopathy of prematurity: a systematic review and meta-analysis. Ophthalmic Surg Lasers Imaging Retina. 2021, 52:673-81. 10.3928\/23258160-20211124-01","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-318026","article-title":"Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial","volume":"106","author":"Wu Z","year":"2022","unstructured":"Wu Z, Zhao J, Lam W, et al.. Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial. Br J Ophthalmol. 2022, 106:975-9. 10.1136\/bjophthalmol-2020-318026","journal-title":"Br J Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001763","article-title":"Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity","volume":"38","author":"Jin E","year":"2018","unstructured":"Jin E, Yin H, Li X, Zhao M. Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity. Retina. 2018, 38:1595-604. 10.1097\/IAE.0000000000001763","journal-title":"Retina"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000166","article-title":"Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II","volume":"22","author":"Autrata R","year":"2012","unstructured":"Autrata R, Krejc\u00edrov\u00e1 I, Senkov\u00e1 K, Holou\u0161ov\u00e1 M, Dole\u017eel Z, Borek I. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol. 2012, 22:687-94. 10.5301\/ejo.5000166","journal-title":"Eur J Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial","volume":"172","author":"Stahl A","year":"2018","unstructured":"Stahl A, Krohne TU, Eter N, et al.. Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr. 2018, 172:278-86. 10.1001\/jamapediatrics.2017.4838","journal-title":"JAMA Pediatr"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"142","author":"Fierson WM","year":"2018","unstructured":"Fierson WM. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2018, 142:e20183061. 10.1542\/peds.2018-3061","journal-title":"Pediatrics"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors","volume":"58","author":"Lyu J","year":"2017","unstructured":"Lyu J, Zhang Q, Chen CL, et al.. Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors. Invest Ophthalmol Vis Sci. 2017, 58:1719-25. 10.1167\/iovs.16-20680","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments","volume":"125","author":"Wallace DK","year":"2018","unstructured":"Wallace DK, Dean TW, Hartnett ME, et al.. A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments. Ophthalmology. 2018, 125:1961-6. 10.1016\/j.ophtha.2018.05.001","journal-title":"Ophthalmology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.10.032","article-title":"Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China","volume":"124","author":"Feng J","year":"2017","unstructured":"Feng J, Qian J, Jiang Y, et al.. Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China. Ophthalmology. 2017, 124:408-9. 10.1016\/j.ophtha.2016.10.032","journal-title":"Ophthalmology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001241","article-title":"Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity","volume":"37","author":"Zhang G","year":"2017","unstructured":"Zhang G, Yang M, Zeng J, et al.. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina. 2017, 37:710-7. 10.1097\/IAE.0000000000001241","journal-title":"Retina"},{"key":"ref34","article-title":"Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up","volume":"109","author":"O'Keeffe N","year":"2016","unstructured":"O'Keeffe N, Murphy J, O'Keefe M, Lanigan B. Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Ir Med J. 2016, 109:355.","journal-title":"Ir Med J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S176021","article-title":"Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis","volume":"12","author":"Wang L","year":"2018","unstructured":"Wang L, Zhang C, Hua R. Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis. Drug Des Devel Ther. 2018, 12:3625-33. 10.2147\/DDDT.S176021","journal-title":"Drug Des Devel Ther"},{"key":"ref36","unstructured":"Covidence - better systematic review management. (2023). Accessed. 09\/11\/2023: https:\/\/www.covidence.org\/."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v049.i05","article-title":"Closing the gap between methodologists and end-users: R as a computational back-end","volume":"49","author":"Wallace BC","year":"2012","unstructured":"Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw. 2012, 49:1-15. 10.18637\/jss.v049.i05","journal-title":"J Stat Softw"},{"key":"ref38","unstructured":"7.7.3.2 Obtaining standard deviations from standard errors and confidence intervals for group means. (2022). Accessed. 09\/11\/2023: https:\/\/handbook-5-1.cochrane.org\/chapter_7\/7_7_3_2_obtaining_standard_deviations_from_standard_errors_and.htm."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13008","article-title":"Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity","volume":"94","author":"Karkhaneh R","year":"2016","unstructured":"Karkhaneh R, Khodabande A, Riazi-Eafahani M, et al.. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta Ophthalmol. 2016, 94:e417-20. 10.1111\/aos.13008","journal-title":"Acta Ophthalmol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.joco.2018.10.008","article-title":"Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity","volume":"31","author":"Roohipoor R","year":"2019","unstructured":"Roohipoor R, Torabi H, Karkhaneh R, Riazi-Eafahani M. Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity. J Curr Ophthalmol. 2019, 31:61-5. 10.1016\/j.joco.2018.10.008","journal-title":"J Curr Ophthalmol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.911095","article-title":"Comparison of intravitreal anti-VEGF agents with laser photocoagulation for retinopathy of prematurity of 1,627 eyes in China","volume":"9","author":"Linghu D","year":"2022","unstructured":"Linghu D, Cheng Y, Zhu X, et al.. Comparison of intravitreal anti-VEGF agents with laser photocoagulation for retinopathy of prematurity of 1,627 eyes in China. Front Med (Lausanne). 2022, 9:911095. 10.3389\/fmed.2022.911095","journal-title":"Front Med (Lausanne)"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen EA","year":"2019","unstructured":"Sukgen EA, Ko\u00e7luk Y. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2019, 257:49-55. 10.1007\/s00417-018-4168-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00334-4","article-title":"Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity","volume":"7","author":"Riazi-Esfahani H","year":"2021","unstructured":"Riazi-Esfahani H, Mahmoudi A, Sanatkar M, Farahani AD, Bazvand F. Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity. Int J Retina Vitreous. 2021, 7:60. 10.1186\/s40942-021-00334-4","journal-title":"Int J Retina Vitreous"},{"key":"ref44","doi-asserted-by":"crossref","DOI":"10.5935\/0004-2749.20150079","article-title":"Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity","volume":"78","author":"Gunay M","year":"2015","unstructured":"Gunay M, Celik G, Gunay BO, Aktas A, Karatekin G, Ovali F. Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol. 2015, 78:300-4.","journal-title":"Arq Bras Oftalmol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14460","article-title":"Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity","volume":"98","author":"Cheng Y","year":"2020","unstructured":"Cheng Y, Zhu X, Linghu D, Liang J. Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity. Acta Ophthalmol. 2020, 98:e1004-8. 10.1111\/aos.14460","journal-title":"Acta Ophthalmol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-021-02188-z","article-title":"Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment","volume":"42","author":"S\u00fcren E","year":"2022","unstructured":"S\u00fcren E, \u00d6zkaya D, \u00c7etinkaya E, Kalayc\u0131 M, Yi\u011fit K, K\u00fcc\u00fck MF, Erol MK. Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment. Int Ophthalmol. 2022, 42:1905-13. 10.1007\/s10792-021-02188-z","journal-title":"Int Ophthalmol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"42","author":"Gunay M","year":"2017","unstructured":"Gunay M, Sukgen EA, Celik G, Kocluk Y. Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res. 2017, 42:462-9. 10.1080\/02713683.2016.1196709","journal-title":"Curr Eye Res"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12339","article-title":"Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity","volume":"92","author":"Moran S","year":"2014","unstructured":"Moran S, O'Keefe M, Hartnett C, Lanigan B, Murphy J, Donoghue V. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity. Acta Ophthalmol. 2014, 92:e496-7. 10.1111\/aos.12339","journal-title":"Acta Ophthalmol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2015.01.009","article-title":"Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser","volume":"19","author":"Isaac M","year":"2015","unstructured":"Isaac M, Mireskandari K, Tehrani N. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. J AAPOS. 2015, 19:140-4. 10.1016\/j.jaapos.2015.01.009","journal-title":"J AAPOS"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang CK","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015, 122:1008-15. 10.1016\/j.ophtha.2014.12.017","journal-title":"Ophthalmology"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003196","article-title":"Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity","volume":"41","author":"Iwahashi C","year":"2021","unstructured":"Iwahashi C, Utamura S, Kuniyoshi K, Sugioka K, Konishi Y, Wada N, Kusaka S. Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity. Retina. 2021, 41:2261-8. 10.1097\/IAE.0000000000003196","journal-title":"Retina"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2016.1264607","article-title":"Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children","volume":"42","author":"Kabata\u015f EU","year":"2017","unstructured":"Kabata\u015f EU, Kurtul BE, Alt\u0131ayl\u0131k \u00d6zer P, Kabata\u015f N. Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children. Curr Eye Res. 2017, 42:1054-8. 10.1080\/02713683.2016.1264607","journal-title":"Curr Eye Res"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.4103\/joco.joco_193_21","article-title":"Comparison of clinical outcomes of intravitreal bevacizumab and aflibercept in type 1 prethreshold retinopathy of prematurity in posterior zone II","volume":"34","author":"Eftekhari Milani A","year":"2022","unstructured":"Eftekhari Milani A, Bagheri M, Niyousha MR, Rezaei L, Hazeri S, Safarpoor S, Abdollahi M. Comparison of clinical outcomes of intravitreal bevacizumab and aflibercept in type 1 prethreshold retinopathy of prematurity in posterior zone II. J Curr Ophthalmol. 2022, 34:87-92. 10.4103\/joco.joco_193_21","journal-title":"J Curr Ophthalmol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2018.0011","article-title":"Anti-vascular endothelial growth factor treatment of retinopathy of prematurity: efficacy, safety, and anatomical outcomes","volume":"32","author":"Kang HG","year":"2018","unstructured":"Kang HG, Choi EY, Byeon SH, Kim SS, Koh HJ, Lee SC, Kim M. Anti-vascular endothelial growth factor treatment of retinopathy of prematurity: efficacy, safety, and anatomical outcomes. Korean J Ophthalmol. 2018, 32:451-8. 10.3341\/kjo.2018.0011","journal-title":"Korean J Ophthalmol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato T","year":"2012","unstructured":"Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, Kusaka S. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012, 153:327-33.e1. 10.1016\/j.ajo.2011.07.005","journal-title":"Am J Ophthalmol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S151225","article-title":"Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis","volume":"13","author":"Cui C","year":"2018","unstructured":"Cui C, Lu H. Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis. Clin Interv Aging. 2018, 13:51-62. 10.2147\/CIA.S151225","journal-title":"Clin Interv Aging"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-311662","article-title":"Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity","volume":"103","author":"Bai Y","year":"2019","unstructured":"Bai Y, Nie H, Wei S, Lu X, Ke X, Ouyang X, Feng S. Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity. Br J Ophthalmol. 2019, 103:494-8. 10.1136\/bjophthalmol-2017-311662","journal-title":"Br J Ophthalmol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S29974","article-title":"Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration","volume":"7","author":"Thomas M","year":"2013","unstructured":"Thomas M, Mousa SS, Mousa SA. Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol. 2013, 7:495-501. 10.2147\/OPTH.S29974","journal-title":"Clin Ophthalmol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3858\/emm.2012.44.1.025","article-title":"The discovery of placenta growth factor and its biological activity","volume":"44","author":"De Falco S","year":"2012","unstructured":"De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med. 2012, 44:1-9. 10.3858\/emm.2012.44.1.025","journal-title":"Exp Mol Med"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.08.008","article-title":"A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration","volume":"118","author":"Zhang M","year":"2011","unstructured":"Zhang M, Zhang J, Yan M, Luo D, Zhu W, Kaiser PK, Yu DC. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology. 2011, 118:672-8. 10.1016\/j.ophtha.2010.08.008","journal-title":"Ophthalmology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/310991-recurrence-of-retinopathy-of-prematurity-following-anti-vascular-endothelial-growth-factor-anti-vegf-therapy-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T15:49:45Z","timestamp":1731080985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/310991-recurrence-of-retinopathy-of-prematurity-following-anti-vascular-endothelial-growth-factor-anti-vegf-therapy-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":62,"URL":"https:\/\/doi.org\/10.7759\/cureus.73286","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,8]]}}}